6 results about "Adoptive immunity" patented technology

The invention relates to an inducible chimeric co-stimulatory receptor (CCR) comprising an intracellular T cell activation dependent localization domain. The invention further relates to an immune cell expressing the inducible CCR, a nucleic acid molecule encoding said inducible CCR, and to a pharmaceutical composition, comprising said immune cell or said nucleic acid molecule. The invention further relates to a method of producing said immune cell and to a method of treating a malignancy, comprising providing immune cells expressing the inducible CCR to a patient in need thereof.

The application belongs to the technical field of biotechnology, and particularly relates to a staged precise regulation in vitro expansion culture method of high-activity gamma delta T cells. In the synergistic activation stage, the complex activator containing zoledronic acid, IL-2, IL-15, IL-12 and IL-21 is used to significantly improve the early activation level of the gamma delta T cells; in the dynamic expansion stage, the concentration of metformin is adjusted step by step to support the continuous and efficient proliferation of the cells; in the gradient maturation stage, the combination system of N-acetyl cysteine, TWS119 and DL-alpha tocopheryl acetate is introduced to help maintain the functional activity and antioxidant state of the cells in the later culture stage. The gamma delta T cells with a purity higher than 90% and an expansion multiple more than 100 times can be obtained by using the method to culture for 10 days, and the cells exhibit significant killing activity to tumor cells, are suitable for the adoptive immunotherapy of tumor and infectious diseases, and have good clinical application prospects.

The application provides a high-efficiency expansion culture method of umbilical cord blood gamma delta T cells and application thereof, and belongs to the technical field of biological medicine. Through a specific two-stage strategy of "initial induction culture + expansion culture", the application is simple in operation, stable in system, and high in success rate, effectively overcomes the defects of limited autologous blood source, unstable expansion and low cell activity in the prior art, and lays a foundation for large-scale preparation and allogeneic application of gamma delta T cells. The umbilical cord blood gamma delta T cells obtained by the method of the application are excellent in quantity, purity, activity and anti-tumor function, and have stronger tumor cell killing ability, and are especially suitable for adoptive immunotherapy. The application breaks through the technical bottleneck of the traditional culture system, provides a high-efficiency, stable and clinically convertible gamma delta T cell expansion scheme, and has important application prospect and market value.

The invention relates to the field of biological medicines, in particular to a TCR55 mutant and application thereof.The TCR55 mutant comprises an alpha chain and a beta chain, the TCR55 mutant is obtained after mutation is conducted on the basis of wild TCR55, and the alpha chain of the TCR55 mutant is a mutant obtained after any one of the following sites on the alpha chain of the wild TCR55 is mutated into histidine, the fourth position D and / or the fifth position E of the CDR2 alpha, and the seventh position A of the CDR3 alpha; or the beta chain of the TCR55 mutant is a mutant obtained by mutating any one of the following on the beta chain of the wild type TCR55 into histidine: the second site N of CDR1beta, the second site A of CDR2beta, the fourth site E and / or the sixth site T of CDR2beta, and the thirteenth site Y of CDR3beta. The mutant can be used for identifying HIV (Pol448-456) / HLA-B35, has high activating power, triggers downstream signal transduction, and can be used for transforming T cells to form specific high-activating-power TCR-T cells for T cell adoptive immunotherapy.

To provide compositions and methods for immune cell modulation.SOLUTION: In one aspect, a composition comprises a population or subpopulation of immune cells, and one or more modulating agents selected from the group consisting of specific compounds. The one or more modulating agents (a) improve therapeutic potential of immune cells for adoptive cell therapy; (b) improve cell expansion, maintenance, and / or differentiation properties of immune cells; (c) improve cell proliferation, cytotoxicity, persistence, cytokine response and secretion, and / or cell recall responses of immune cells; and / or (d) increase the number or ratio of a desired immune cell subpopulation.SELECTED DRAWING: Figure 1A